Twenty-Twenty Hindsight: An Adjuvant Breast Cancer Trial Through the Retrospectoscope
Mené sur 3 871 patientes atteintes d'un cancer du sein de stade précoce, cet essai compare l'efficacité, du point de vue de la survie sans récidive, et la toxicité du paclitaxel avec une combinaison doxorubicine-cyclophosphamide en traitement adjuvant (durée médiane de suivi : 6,1 ans)
Successful conduct of phase III clinical trials can be challenging, particularly in the adjuvant breast cancer setting, where relatively good-prognosis disease can result in low outcome event rates, thus requiring large sample sizes with prolonged follow-up, even with the simplest study design. The report by Shulman et al that accompanies this editorial highlights some of the trials and tribulations of conducting a complex, large-scale, adjuvant breast cancer trial, the ultimate aim of which is to provide results that are relevant to usual clinical practice...
Journal of Clinical Oncology , éditorial en libre accès, 2014